Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. Welcome to Myriad Genetics' second quarter 2026 Financial Earnings Conference Call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you'll need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To destroy your question, Please press star one again. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your speaker for today, Matt Scalio. Please go ahead. Good afternoon and welcome to Merit Genetics second quarter 2026 earnings call. During the call, we will review financial results we released today and afterwards we will host a Q&A session. Our earnings release was issued this afternoon on form 8K and can be found on our website at investor.myriad.com. I'm Matt Scalo, Senior Vice President of Investor Relations. On the call with me today are Sam Raha, our President and Chief Executive Officer, Ben Wheeler, our Chief Financial Officer, and Brian Donnelly, our Chief Commercial Officer. Joining for Q&A will be Mark Verratti, our Chief Operating Officer. This call can be heard live via webcast at investor.mary.com and a recording will be archived in the investor section of our website along with this slide presentation. Please note that some of the information presented today contains projections or other forward-looking statements regarding future events or the future financial performance of the company. These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations for a variety of reasons. We refer you...